Kymera Therapeutics KYMR
- Market cap
- $10.6B
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 101×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $105M
- +135% on a year ago
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- −2.2%
Kymera Therapeutics trades at 101× sales. Its trailing earnings are negative, so it has no PE. Revenue was $105M over the last twelve months, up 135% on a year earlier.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $4.7M−51% | $47.9M+197% | $10.3M+9% | $25.6M+55% | $3.7M−21% | $7.4M−85% | $22.1M+115% | $11.5M−55% | $2.8M−26% | $2.9M−61% | $34.4M+56% | $65M+466% | |
| R&D | $48.1M+10% | $53M+23% | $48.8M+16% | $59.2M+29% | $60.4M+26% | $71.8M+36% | $80.3M+64% | $78.4M+32% | $74.1M+23% | $83.8M+17% | $98.2M+22% | $119.5M+52% |
| SG&A | $14.1M+34% | $14.2M+22% | $14.4M+14% | $17.4M+23% | $15.5M+10% | $16.3M+15% | $16.3M+13% | $17.6M+2% | $17.3M+12% | $16.9M+4% | $20.4M+25% | $21.1M+20% |
| −$57.5M+28% | −$19.3M−50% | −$57.8M+28% | −$50.9M+17% | −$72.1M+25% | −$80.8M+318% | −$74.4M+29% | −$84.6M+66% | −$92.5M+28% | −$97.9M+21% | −$84.2M+13% | −$75.6M−11% | |
| Net income | −$52.9M+23% | −$14.4M−59% | −$48.6M+19% | −$42.1M+8% | −$62.5M+18% | −$70.8M+392% | −$65.6M+35% | −$76.6M+82% | −$82.2M+32% | −$87M+23% | −$69.2M+6% | −$61.2M−20% |
| −$0.90+14% | −$0.25−58% | −$0.69−1% | −$0.58−13% | −$0.82−9% | −$0.88+252% | −$0.82+19% | −$0.95+64% | −$0.94+15% | −$0.97+10% | −$0.71−13% | −$0.62−35% | |
| 58.4M+7% | 58.5M+1% | 70.8M+22% | 73.1M+25% | 76.1M+30% | 80.1M+37% | 80.1M+13% | 80.4M+10% | 87.3M+15% | 89.9M+12% | 97.5M+22% | 98.2M+22% |
EPS, diluted: 7 periods, Q4 FY19 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 7 periods, Q4 FY19 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Biotechnology nearest Kymera Therapeutics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| KYMRKymera Therapeutics | $10.6B | n/m | n/a | n/m | 101× | +135% | n/m |
| TECHBIO-TECHNE | $11.4B | 63.2× | 62.0× | n/m | 9.4× | −0% | 15.0% |
| RGENRepligen | $9.8B | 237× | 123× | n/m | 12.4× | +16% | 5.3% |
| KRYSKrystal Biotech | $8.8B | 37.1× | 42.5× | n/m | 19.9× | +23% | 54.8% |
| HALOHalozyme Therapeutics | $14.6B | 38.5× | 21.3× | n/m | 8.8× | +41% | 24.9% |
| NBIXNeurocrine Biosciences | $14.8B | 21.3× | 42.6× | n/m | 4.4× | +34% | 20.9% |
| EXELExelixis | $17.4B | 22.1× | 22.7× | n/m | 7.1× | +9% | 35.3% |
| ALNYAlnylam Pharmaceuticals | $21.2B | 26.7× | 68.2× | 18.9× | 4.4× | +95% | 16.8% |
| INCYIncyte | $24.3B | 15.3× | 36.5× | 51.3× | 4.2× | +27% | 27.7% |
| UTHRUnited Therapeutics | $25.9B | 21.6× | 14.2× | 22.6× | 8.2× | +2% | 41.6% |
| ONCBeOne Medicines | $40.2B | 63.2× | 67.6× | 45.0× | 6.6× | +34% | 10.7% |
| Peer median | $16.1B | 31.9× | 42.6× | 33.8× | 7.7× | +25% | 22.9% |
Investors who own it
Investors we follow who held Kymera Therapeutics at the end of Jun 30, 2026, from their 13F filings.
- Ron BaronBaron Capital0.0% of portfolio
More on Kymera Therapeutics
Each number over time
Where it ranks
Its groups
About
- Industry
- Biotechnology
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .